Evidence map›Paper›PMID 36157119›Full record

ArticleWorld journal of gastroenterology2022

Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.

Gwang Hyeon Choi, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, In Hee Kim, Sung Bum Cho, Han Chu Lee, Jeong Won Jang, Moran Ki, Hwa Young Choi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Predicting hepatitis C infection via machine learning.American journal of translational research · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gwang Hyeon ChoiDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, South Korea.
Eun Sun JangDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, South Korea.
Young Seok KimDepartment of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, South Korea.
Youn Jae LeeDepartment of Internal Medicine, Inje University Busan Paik Hospital, Busan 47392, South Korea.
In Hee KimDepartment of Internal Medicine, Chonbuk National University Hospital, Jeonju 54907, Jeonbuk, South Korea.
Sung Bum ChoDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun 58128, South Korea.
Han Chu LeeDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea.
Jeong Won JangDepartment of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea.
Moran KiCancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, South Korea.
Hwa Young ChoiCancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, South Korea.
Dahye BaikCancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, South Korea.
Sook-Hyang JeongDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, South Korea. jsh@snubh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProspective studies of the long-term outcomes of patients with hepatitis C virus (HCV) infection after treatment with interferon-based therapy (IBT) or direct-acting antivirals (DAA) are limited in many Asian countries.

aimTo elucidate the incidences of hepatocellular carcinoma (HCC) and death/transplantation based on treatment with IBT or DAA, to compare the outcomes of the sustained virologic response (SVR) to IBT and DAA, and to investigate outcome-determining factors after SVR.

methodsThis cohort included 2054 viremic patients (mean age, 57 years; 46.5% male; 27.4% with cirrhosis) prospectively enrolled at seven hospitals between 2007 and 2019. They were classified as the untreated group (

resultsDuring a median of 4.1 years of follow-up, HCC and death/transplantation occurred in 113 and 206 patients, respectively, in the entire cohort. Compared with the untreated group, the incidences of HCC and death/transplantation were significantly lower in the IBT group [adjusted hazard ratio (aHR) 0.47, 95%CI: 0.28-0.80 and aHR 0.28, 95%CI: 0.18-0.43, respectively] and the DAA group (aHR 0.58, 95%CI: 0.35-0.96, and aHR 0.19, 95%CI: 0.20-0.68, respectively). Among 1268 patients who attained SVR with IBT (

conclusionTreatment and achieving SVR with either IBT or DAA significantly reduced the incidences of HCC and mortality in the Asian patients with HCV infection. The risks of HCC and mortality were not significantly different regardless of whether SVR was induced by IBT or DAA.

Indexed as

Carcinoma, HepatocellularHepatitis CHepatitis C, ChronicLiver NeoplasmsAntiviral AgentsCohort StudiesFemaleHepacivirusHumansInterferonsLiver CirrhosisMaleMiddle AgedProspective StudiesSustained Virologic ResponseAntiviral AgentsInterferonsDirect-acting antiviralHepatitis C virusHepatocellular carcinomaMortalitySustained virologic response

Identifiers

PMID36157119
PMCPMC9403421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.